Evidence map›Paper›PMID 32934078›Full record

ArticlemBio2020

CD4

Gang Zhang, Grant R Campbell, Qiangzhe Zhang, Erin Maule, Jonathan Hanna, Weiwei Gao, Liangfang Zhang, Stephen A Spector

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Engineered Cell Membrane-Derived Nanoparticles in Immune Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Gang Zhang *Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Grant R Campbell *Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0003-3927-1994
Qiangzhe ZhangDepartment of Nanoengineering, University of California, San Diego, La Jolla, California, USA.
Erin MauleDivision of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Jonathan HannaDivision of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Weiwei GaoDepartment of Nanoengineering, University of California, San Diego, La Jolla, California, USA.
Liangfang ZhangDepartment of Nanoengineering, University of California, San Diego, La Jolla, California, USA.
Stephen A SpectorDivision of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California, USA saspector@ucsd.edu.ORCID 0000-0002-1882-4855
University of California San Diego · US

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
University of California, San Diego Clinical Trial UnitUM1AI069536 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STEPHEN A SPECTOR · 2012 to 2026
$34.0M
University of California, San Diego Clinical Trial UnitU01AI069536 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SPECTOR, STEPHEN A · 2007 to 2011
$5.4M
Nanopeptide Targeting of HIV-CNS Reservoirs without ReactivationR01NS104015 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SPECTOR, STEPHEN A · 2017 to 2021
$2.9M
Modulating Autophagy to Eradicate HIV-1 from CNS ReservoirsR01NS084912 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SPECTOR, STEPHEN A · 2013 to 2017
$1.9M
NIAID NIH HHS U01 AI069536NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI069536NIAID NIH HHS UM1 AI106716NINDS NIH HHS R01 NS084912NINDS NIH HHS R01 NS104015
6 · The paper itself

Abstract

Therapeutic strategies that provide effective and broad-spectrum neutralization against HIV-1 infection are highly desirable. Here, we investigate the potential of nanoengineered CD4

Indexed as

AutophagyAdolescentAdultAgedAntibodies, MonoclonalAntibodies, NeutralizingCD4-Positive T-LymphocytesEpitopesFemaleHEK293 CellsHIV-1HIV AntibodiesHIV InfectionsHumansMaleMiddle AgedAntibodies, MonoclonalAntibodies, NeutralizingEpitopesHIV AntibodiesautophagyCD4+ T cellHIVhuman immunodeficiency virusmacrophagenanoparticleneutralizationneutralizing antibodiesphospholipasephospholipase D

Identifiers

PMID32934078
PMCPMC7492730
OpenAlexW3086932903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.